

	TOTAL (n=45)	Group 1 (n=24) Caphosol → Saline	Group 2 (n=21) Saline → Caphosol	
Age, Median(<i>range</i>)	6.5 (2.1, 17.1)	6.0 (2.1, 14.7)	7.2 (3.1, 17.1)	CNS - Central nervous system
Sex, N (%)				IQR - Interquartile range
Female	20 (44 %)	13 (54 %)	7 (33 %)	WBC - White blood cell count
Male	25 (56 %)	11 (46 %)	14 (67 %)	ANC - Absolute neutrophil count
Diagnosis, N (%)				CRP - C-reactive protein
Hematological malignancy	28 (62 %)	13 (54 %)	15 (71 %)	
Solid tumor	7 (16 %)	4 (17 %)	3 (14 %)	
CNS tumor	10 (22 %)	7 (29 %)	3 (14 %)	
Discontinued, N (%)	13 (29 %)	6 (25 %)	7 (33 %)	
Cycle 1				
Treatment, N (%)				
High-dose methotrexate	27 (60 %)	13 (54 %)	14 (67 %)	
Other chemotherapy	18 (40 %)	11 (46 %)	7 (33 %)	
Blood values, median (<i>IQR</i>)				
WBC (10 ⁹ /l)	3.8 (2.8, 5.2)	3.5 (2.8, 4.6)	3.9 (3.3, 5.3)	
ANC (10 ⁹ /l)	1.6 (0.9, 2.3)	1.6 (0.9, 2.1)	1.5 (0.9, 2.3)	
CRP (mg/l)	0 (0, 3)	0 (0, 1)	0 (0, 4.4)	CRP values coded as <5 or <1 were treated as zeros.
Cycle 2				
Treatment, N (%)				
High-dose methotrexate	27 (60 %)	14 (58 %)	13 (62 %)	
Other chemotherapy	17 (38 %)	10 (42 %)	7 (33 %)	
<i>Not available</i> ^a	1 (2 %)	0 (0 %)	1 (5 %)	^a Subject had finished his treatment protocol before the second chemotherapy cycle.
Blood values, median (<i>IQR</i>)				
WBC (10 ⁹ /l)	3 (1.9, 4.6)	2.5 (1.9, 4.3)	3.3 (2.3, 4.6)	
ANC (10 ⁹ /l)	1.2 (0.7, 2.1)	1.1 (0.8, 2)	1.4 (0.6, 2.1)	
CRP (mg/l)	0 (0, 1.8)	0 (0, 1.4)	0 (0, 4.6)	